Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives $54.25 Consensus PT from Brokerages

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has received a consensus rating of “Moderate Buy” from the eighteen analysts that are currently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $54.25.

TNDM has been the subject of a number of recent research reports. UBS Group upgraded Tandem Diabetes Care to a “hold” rating in a research note on Friday, August 2nd. Wells Fargo & Company upped their target price on shares of Tandem Diabetes Care from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. The Goldman Sachs Group started coverage on shares of Tandem Diabetes Care in a research note on Friday, October 4th. They set a “neutral” rating and a $46.00 price target on the stock. Canaccord Genuity Group began coverage on Tandem Diabetes Care in a research note on Thursday, August 8th. They issued a “buy” rating and a $57.00 price objective for the company. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $55.00 target price (up from $50.00) on shares of Tandem Diabetes Care in a report on Friday, August 2nd.

Tandem Diabetes Care Trading Down 3.6 %

Tandem Diabetes Care stock opened at $28.59 on Tuesday. Tandem Diabetes Care has a one year low of $17.33 and a one year high of $53.69. The business’s fifty day moving average is $38.05 and its 200 day moving average is $41.76. The stock has a market capitalization of $1.88 billion, a PE ratio of -14.93 and a beta of 1.36. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The business had revenue of $243.97 million for the quarter, compared to analysts’ expectations of $224.14 million. During the same quarter in the prior year, the business earned ($0.38) EPS. The business’s revenue for the quarter was up 31.4% compared to the same quarter last year. On average, sell-side analysts predict that Tandem Diabetes Care will post -1.73 EPS for the current year.

Institutional Trading of Tandem Diabetes Care

A number of institutional investors and hedge funds have recently bought and sold shares of TNDM. Brooklyn Investment Group bought a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at about $28,000. Assetmark Inc. bought a new position in Tandem Diabetes Care during the third quarter valued at approximately $29,000. ORG Wealth Partners LLC purchased a new position in Tandem Diabetes Care during the 3rd quarter valued at approximately $30,000. ORG Partners LLC purchased a new position in Tandem Diabetes Care during the 2nd quarter valued at approximately $31,000. Finally, Headlands Technologies LLC bought a new stake in Tandem Diabetes Care in the 1st quarter worth approximately $35,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.